Comparing the current results to its competitors, Passage Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 130.99 %, recorded in the same quarter.
Passage Bio Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical sectors, focusing on gene therapies and genetic medicine. Its primary competitor for the treatment of frontotemporal dementia linked to progranulin mutations (FTD-GRN) is AviadoBio Ltd, which initiated a Phase 1/2 gene therapy trial in 2023 and holds an exclusive option and licensing agreement with Astellas Pharma Inc. Additional entities engaged in preclinical research for FTD-GRN include Kyowa Kirin Co., Ltd. and QurAlis Corporation. Denali Therapeutics Inc., in collaboration with Takeda Pharmaceutical Company Limited, is conducting a Phase 1/2 clinical trial involving recombinant progranulin protein. In the area of Huntington's Disease (HD), Evox Therapeutics Ltd, Latus Bio, Inc., uniQure N.V., and Voyager Therapeutics, Inc. are developing preclinical gene therapy programs targeting the DNA repair protein MSH3. Other companies are investigating alternative methods to target MSH3 and other DNA repair proteins such as FAN1. Several competitors possess greater resources and may develop products with improved safety, efficacy, or convenience, which could affect the company's commercial prospects.
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
Protalix Biotherapeutics Inc. operates under a business model focused on the development, production, and commercialization of recombinant therapeutic proteins using plant cell culture technology, aiming to address unmet medical needs and provide innovative treatment options to patients worldwide.
Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients' lives.
Sources:
Passage Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Passage Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
